

Short CV

David Ferry BSc PhD MB ChB FRCP

David graduated from Leicester medical school in the UK in 1987. During his medical studies he completed his PhD in molecular pharmacology under Professor Glossmann at Giessen University in Germany as a Deutscher Akademischer Austausch Dienst (DAAD) scholar. David has been in oncology since he became a Cancer Research Campaign medical Lecturer in 1990 at Birmingham University UK, working for Professor Cullen on lung cancer and esophageal cancer. During his training he worked under Professor David Kerr, developing an interest in GI cancer and phase I trials. He led the first phase I trial with a tyrosine kinase the flavonoid quercetin (Ferry et al, 1996, Clin Can Res, 2, 659-68). He was also involved in the first gefitinib phase I trial. After becoming a Senior Lecturer in 1995 he worked on drug resistance, particularly on the structure and function of ABC transporter P-glycoprotein and developed extensive trials based practice in GI and thoracic oncology becoming a Professor of Medical Oncology in 2003. He has published over 200 cited works with over 9500 citations and a Google Scholar H factor of 52. At the beginning of 2014 he moved from academia to the pharmaceutical industry, with Lilly and is the Global Senior Medical Director for ramucirumab, based in the US.

